New Lease Of Life For Merck Serono Reject Cilengitide

Basing a company around a high-profile failed drug candidate is not for the faint hearted, but that's exactly what Dr. John March is doing with Merck Serono reject cilengitide. Scrip asked him what it will take to turn the cilengitide story around.